Fewer Black and Hispanic people than white people who are at risk of contracting HIV take preventive medication to keep them from catching the virus, both in Michigan and across the U.S., according to an Emory University study presented at the 24th International AIDS Conference in Montreal.
The study looked at the percentage by race of new cases and compared that with the percentage taking PrEP, a medicine that can prevent people from contracting the HIV virus that causes AIDS.
The study was released on AIDSVu, an online data site presented by Emory University’s Rollins School of Public Health in partnership with Gilead Sciences Inc., and the Center for AIDS Research at Emory University. PrEP (short for Pre-Exposure Prophylaxis) is manufactured by Gilead. The center is also funded by the National Institutes of Health.
